Sickle cell anemia (SCA) is one of the commonest severe inherited disorders. Nevertheless, effective treatments remain inadequate and novel ones are avidly sought. A promising advance has been the design of novel compounds which react with hemoglobin S (HbS) to increase oxygen (O 2 ) affinity and reduce sickling. One of these, voxelotor (GBT440), is currently in advanced clinical trials. A structural analogue, GBT1118, was investigated in the current work. As RBC dehydration is important in pathogenesis of SCA, the effect of GBT1118 on RBC cation permeability was also studied. Activities of P sickle , the Gardos channel and the KCl cotransporter (KCC) were all reduced. Gardos channel and KCC activities were also inhibited in RBCs treated with Ca 2+
Introduction
Sickle cell anemia (SCA) represents one of the commonest severe inherited disorders affecting millions of people worldwide (Piel et al. 2013 ). The etiology is well knownin most cases a single amino acid substitution at the sixth position of the b chain of Hb with valine replacing glutamic acid produces HbS rather than the normal adult HbA (Rees et al. 2010) . About two-thirds of cases are homozygous for HbS (HbSS genotype) while about onethird are heterozygous for HbS and HbC, in which the b6 amino acid substitution is lysine instead of valine. There are, in addition, a number of other rarer genotypes (Rees et al. 2010) .
The pathogenesis of SCA is complex but the precipitating event is the ability of deoxygenated HbS molecules to adhere to each other (Steinberg 1999 ). The resultant polymers are highly organized with 14-stranded helices of insoluble HbS, sufficiently rigid to alter RBC shape -the sickling shape change -distorting the normal biconcave morphology into sickles and other bizarre shapes. The consequence is sticky, fragile RBCs with greatly reduced life-span and poor rheological features. Chronic anemia ensues. In addition, sickle cells also occlude small blood vessels with symptoms of ischemia and organ damage, including pain, strokes, nephropathy, osteonecrosis, dactylitis, leg ulcers, and priapism. Notwithstanding, the clinical picture is markedly variable between patients with some mildly or even subclinically affected, while others present with much more severe complications requiring frequent hospitalization and support for multiple organ damage (Steinberg 1999; Rees et al. 2010) . In most cases, it is not known why the clinical severity has a variable course.
Despite its high incidence worldwide, treatment remains largely supportive (Rees et al. 2010 ). Blood transfusion, neonatal vaccination, and provision of antibiotics have all been useful in reducing mortality but specific therapies remain inadequate. Hydroxyurea has shown some success (Platt et al. 1984; Charache et al. 1987) . This reagent appears to work by increasing the expression of fetal Hb (HbF), which dilutes RBC HbS and inhibits polymer formation. Hydroxyurea is not without its problems, however, being potentially teratogenic and showing a variable response between patients (Rees 2011 ). There has therefore been considerable effort at discovering new therapies (Gibson et al. 2015) .
A particularly fruitful approach has been the design of adducts which interact directly with HbS and reduce its tendency to polymerize. These increase the oxygen affinity of HbS and "left shift" the Hb oxygen equilibrium curves (OECs) (Safo and Kato 2014) . Since their inception in the 1970s, a large number of compounds have been tested including BW12C (Fitzharris et al. 1985) and tucaresol (Rolan et al. 1995) . Until recently, the most promising was 5-hydroxymethyl-2-furfural (5HMF or Aes-103; Abdulmalik et al. 2005) but none progressed to phase 3 clinical trials until the design of voxelotor (also known as GBT440) by Global Blood Therapeutics (Lehrer-Graiwer et al. 2015; Dufu et al. 2016; Oksenberg et al. 2016; Metcalf et al. 2017; Howard et al. 2019) . Voxelotor increased the HbS O 2 affinity, has excellent pharmacokinetic properties, reduces in vivo sickling, is well tolerated, and is currently in phase 3 clinical trials.
GBT1118 is a structural analogue of voxelotor with similar pharmacological properties ).
An important feature of RBCs from SCA patients is their increased cation permeability (Lew and Bookchin 2005) . As a consequence, cells lose KCl and osmotically obliged water with subsequent RBC shrinkage and elevation of the concentration of intracellular HbS ([HbS] ). Clinically, this is particularly significant as the lag time to polymerization is inversely proportional to [HbS] 15-30 (Eaton and Hofrichter 1987) . A small shrinkage means that cells are markedly encouraged to undergo sickling as they traverse hypoxic regions of the microvasculature. Three transport systems are predominantly involved (Lew and (Gibson and Ellory 2003; Lew and Bookchin 2005) . The Gardos channel is encoded by KCNN4 (Hoffman et al. 2003) , while there are three isoforms of the KCl cotransporter found in RBCs, KCC1, 3, and 4, encoded by the genes SLC12A4, 6 & 7 (Pan et al. 2011; Arroyo et al. 2013) . The molecular identity of P sickle , however, remains elusive although a possible involvement of PIEZO1 has been proposed recently (Zarychanski et al. 2012; Gallagher 2017) .
Understanding the mechanisms involved in KCl loss and uncovering potential inhibitors have represented an additional therapeutic approach. Over the years, potential inhibitors to all three transport systems have been investigated (see table 1, Gibson et al. 2015) . A particularly promising compound was the clotrimazole analogue ICA17043 known as Senicapoc (Ataga et al. 2008; Ataga and Stockler 2009) . Senicapoc inhibits activity of the Gardos channel in vitro and thereby reduces solute loss and shrinkage. In SCA patients in vivo, Senicapoc was also effective in increasing RBC hydration. Episodes of pain, however, were not reduced and this agent was discontinued (Ataga et al. 2008) , perhaps prematurely. The search for more effective compounds continues.
Here, we describe the in vitro effects GBT1118 on RBCs from SCA patients. We confirmed a marked increase in O 2 affinity and reduction in RBC sickling. In addition, the reagent also inhibited all three dehydrating pathways in sickle RBCs, with increase in RBC hydration, and a reduction in RBC fragility. These findings are particularly exciting as they suggest that GBT1118 may have multiple actions, reducing sickling by both increasing oxygen affinity and also by maintaining a lower (Fig. 1 ).
Solutions and tonometry
The standard saline (Cl-MBS) comprised (in mM): 145 NaCl, 1. were prepared in DMSO and used at a final concentration of 5 lmolÁL À1 . Whole blood was washed five times in N-MBS to remove Cl À , plasma, and buffy coat. RBC suspensions were then preincubated at 20% hematocrit (Hct) in eppendorf tubes with or without GBT1118 (up to 3 mmolÁL À1 GBT1118, dissolved in DMSO -untreated RBCs were exposed to the same final concentration of DMSO) for 45 min at 37°C and then placed in tonometers (Eschweiler, Kiel, Germany) to equilibrate at the requisite O 2 tension before flux measurement (still in N-MBS). Tonometers were flushed with warm, humidified gas mixtures, supplied at the appropriate O 2 tension using a W€ osthoff gas mixing pump (Speake et al. 1997 ). For flux measurements, RBC suspensions were then diluted 10-fold into flux tubes, still equilibrated at the required O 2 tension. Where its effects were investigated, tonometers and flux tubes also contained 0.1-1 mmolÁL ) for 60 min at 37°C at 20% hematocrit (Hct) after which O 2 saturation and sickling were measured at O 2 tensions of 150, 40, 30, 20, 10, and 1.6 mmHg. GBT1118 remained present throughout the assay. O 2 saturation was measured spectrophotometrically using a Hemox analyzer. RBC aliquots were then removed from the sample chamber were fixed with 2% glutaraldehyde for morphometric analysis by light microscopy. Full details are given in the Methods. Data are from a single representative experiment. was present during preincubation with GBT1118 after which aliquots were again diluted 10-fold into flux tubes. For CLT, dissolved in DMSO, appropriate controls were all treated with the same concentration of solvent (0.1% final).
Measurements of O 2 affinity and RBC sickling
Hemoglobin O 2 dissociation curves and RBC sickling were simultaneously evaluated using a Hemox analyzer (TCS Scientific). Whole blood was incubated for 60 min at 37°C with various concentrations of GBT1118 (in 2% DMSO) followed by transfer to the sample chamber of the Hemox analyzer. For RBCs untreated with GBT1118, blood was incubated with 2% DMSO. The blood samples were then saturated with compressed air and flushed with pure N 2 to deoxygenate in the Hemox analyzer. The absorbance at wavelengths that correspond to the isosbestic point (570 nm) and deoxy-Hb (560 nm 
Measurement of RBC water content
The effect of GBT1118 (45 min preincubation) was investigated on RBC volume, in cells incubated in Cl-MBS under full oxygenation or deoxygenation for 60 min at 37°C. RBC water content was measured by the wet weight -dry weight method (Borgese et al. 1991) . In brief, after incubation for 60 min at 5% Hct, RBCs were pelleted by centrifugation at 12,000 g for 15 min at 4°C. The extruded pellet was weighed immediately (to an accuracy of 0.01 mg) and again after drying for 18 h at 95°C. Water content was expressed as ml water per g dry cell solids (ml/g d.c.s.).
K + flux measurements
To determine the activity of the K + transport pathways, K + influx was measured at 37°C using 86 Rb + as a congener for K + (Dunham and Ellory 1981; Hannemann et al. 2011 
Statistics
Results are presented as means AE S.E.M. of n observations in RBC samples taken from different individuals. Where appropriate, comparisons were made using paired student t tests. When nonelectrolyte hemolysis was measured over time, multiple t tests followed by Holm-S ıd ak corrections for multiple comparisons were used (Graphpad Prism 6; CA, USA). Correlations in Figure 2C were made using the Pearson correlation test. The level of significance used was P < 0.05.
Results
The effect of GBT1118 on oxygen affinity, RBC sickling, and cation permeability
In the preliminary set of experiments, the effect of GBT1118 on O 2 saturation and sickling was confirmed in whole blood from SCA patients (Fig. 1A and B) . The P 50 of untreated blood was about 31 mmHg, in agreement with previously published values (Milner 1974) . When whole blood (20% hematocrit) was incubated with GBT1118 at increasing concentrations (0.3, 0.6, and 1.0 mmolÁL À1 ), the P 50 reduced progressively to 24, 9, and 4 mmHg, respectively (Fig. 1A) . As expected, GBT1118 also reduced hypoxia-induced sickling (Fig. 1B) .
In the absence of GBT1118, 50% of the total RBC population were sickled at an O 2 tension of 30 mmHg. In contrast, relatively lower O 2 tensions of 20, 8, and 4 mmHg were required to achieve 50% sickling in the presence of GBT1118 (0.3, 0.6, and 1.0 mmolÁL À1 , respectively), (Fig. 1B) . The effect of different concentrations of GBT1118 was also measured on the main cation transporters of sickle cells. As the concentration of GBT118 was increased, P sickle , Gardos channel, and KCC were all progressively inhibited (shown in Fig. 2 The effect of GBT1118 on the activities of the two conductive channels, P sickle and the Gardos channel, is shown in Figure 3A -D. At all three O 2 tensions, there was significant inhibition of both channels, reaching inhibitions of 48 AE 9% and 89 AE 4% for P sickle and Gardos channel activities under fully deoxygenated conditions, and 51 AE 12% and 50 AE 16% at 20 mmHg ( Fig. 3A and B) . When the two channels were compared, there was significant correlation of their activities in untreated RBCs (Fig. 3C , P < 0.02). This correlation agrees with the ) and bumetanide (10 lmolÁL À1 ) were also present for all influx measurements. Histograms represent means AE S.E.M., n = 3. *P < 0.05; ** P < 0.01. postulate that entry of Ca 2+ via P sickle results in subsequent Gardos channel activation. In the presence of GBT1118, correlation was lost (P = 0.13), probably as channel inhibition reduced the signal-to-noise ratio.
We also tested whether GBT1118 might affect the Gardos channel directly using pharmacological elevation of RBC [Ca 2+ ] i by means of the ionophore A23187 (6 lmolÁL À1 ) (Fig. 3D) . In the presence of GBT1118, Gardos channel activation was still reduced in Ca 2+ -loaded RBCs. The V max and t 1/2 in the absence and presence of GBT1118 were 59.9 AE 0.4 and 52.1 AE 3.4 mmol K + (L cells.h) À1 , and 96 AE 24 and 150 AE 36 sec, respectively, indicative of a direct effect of GBT1118 on the channel (P < 0.001).
The effect of GBT1118 on the activity of the KCl cotransporter in RBCs from SCA patients
The third transporter involved in dehydration of sickle cells is the KCC. The effect of GBT1118 was again investigated on this system. At all three O 2 tensions, KCC activity was reduced, significantly under fully oxygenated and fully deoxygenated conditions, with inhibitions of 55 AE 6% and 62 AE 13%, respectively (Fig. 4A ). Inhibition was also observed at the intermediate O 2 tension (40 AE 16%) ( Fig. 4A , P < 0.05 in normalized fluxes). To investigate whether GBT1118 had its effect on KCC activity via the regulatory protein kinase and phosphatase enzymes or directly on the transporter, its action was examined in RBCs pretreated with NEM. NEM is thought to act by preventing the activity of an inhibitory protein kinase upstream from the transporter, thereby maximally stimulating KCC activity. In both control cells untreated with NEM and those pretreated with NEM (1 mmolÁL À1 , for 45 min), GBT1118 produced significant inhibition (Fig. 4B) . These findings are consistent with an action of GBT1118 at least in part directly on the KCC transport protein. Similar findings were observed in normal RBCs from HbAA individuals in which NEM-stimulated KCC activity declined from 1.500 AE 0.007 in the absence of GBT1118 (1 mmolÁL À1 ) to 0.200 AE 0.020 in its presence.
The effect of GBT1118 on volume of RBCs from SCA patients
Through its inhibitory effects on all three cation pathways involved in dehydration of sickle cells, GBT1118 would be expected to maintain RBC hydration. This was investigated under fully oxygenated and fully deoxygenated conditions (Fig. 5) at pH 7 to be consistent with experiments on transport pathways. Results showed that GBT1118 significantly increased RBC hydration at 100 and 0 mmHg O 2 (P < 0.02 and P < 0.002, respectively). Its inhibitory effects on the dehydrating ion pathways provide an explanation for this although an effect on water channels, for example, AQP1, cannot be excluded.
The effect of GBT1118 on hemolysis of RBCs from SCA patients
The final series of experiments examined the action of GBT1118 on an RBC hemolysis assay. In this assay, RBCs are deoxygenated in isosmotic sucrose solutions and incubated for up to 60 min. In RBCs pretreated with GBT1118, there was significant inhibition of RBC hemolysis from 10 min onwards, reaching a level of 78 AE 3% after 60 min (Fig. 6 ). Taken together, GBT1118 appears to stabilize the RBC membrane as well as increasing O 2 affinity, reducing sickling and inhibiting the major cation transport pathways.
Discussion
GBT1118 is an analogue of voxelotor (GBT440) with similar pharmacological properties. It was used here to investigate its effect on the RBCs transporter systems associated with cell dehydration. In whole blood, GBT1118 elicits a marked reduction in the P 50 for O 2 saturation being several fold more active than 5HMF. There is, concomitantly, a marked reduction in RBC sickling. A compound with such properties combining antisickling activities as well as beneficial effects on RBC hydration may well be effective in ameliorating complications in SCA patients. The present results are significant because they show that GBT1118, in addition to its effect on O 2 affinity and sickling, has a marked inhibitory effect on the three cation pathways most commonly associated with RBC dehydration (Lew and Bookchin 2005) : P sickle , the Gardos channel, and the KCC. These effects were more pronounced at concentrations (1 mM) higher than that needed for antisickling activities (0.3 mmolÁL À1 ). The correlation between activities of P sickle and the Gardos channel, at least in RBCs untreated with GBT1118, indicate that part of its effect is mediated by decreased Ca 2+ entry through the nonspecific cation conductance activated by HbS polymerization and the sickling shape change. In addition, however, GBT1118 was also an effective inhibitor of the Gardos channel in RBCs pharmacologically loaded with Ca 2+ , conditions which circumvent any requirement for Ca 2+ entry via P sickle . In the presence of GBT1118, Gardos channel V max was reduced and t 1/2 increased.
The activity of KCC, the third cation transporter implicated in RBC dehydration, was also markedly inhibited by GBT1118. This transporter is around 50 times more . Histograms are means AE S.E.M., n = 5. *P < 0.05, ***P < 0.001. ] (Borgese et al. 1991) . Histograms are means AE S.E.M., n = 5. *P < 0.05, **P < 0.01. -free N-MBS at 37°C for 45 min. They were then incubated in isosmotic sucrose solution in Eschweiler tonometers and equilibrated with nitrogen for 60 min. For treated red cells, GBT1118 was present throughout flux measurement. Hemolysis was determined by removing serial aliquots of RBC suspension, pelleting intact RBCs, measuring optical density of the supernatant at 540 nm and was expressed as a percentage of total hemolysis, as determined by lysing a RBC aliquot using Triton X-100 (0.1%). Data points represent means AE S.E.M., n = 5. ***P < 0.001. (Brugnara et al. 1986 ). In RBCs from normal HbAA individuals, KCC activity is very low or absent by the time young RBCs have matured (Hall and Ellory 1986) , and it becomes refractory to the usual physiological stimuli such as increased volume or low pH. As it remains amenable to pharmacological activation, this maturation is presumably through loss of its regulatory protein kinase/phosphatase cascade (Gibson and Ellory 2003) , while the transporter remains present in the RBC membrane.
The activity of KCC in sickle cells also shows an abnormal O 2 dependence (Gibson et al. 1998) . In normal RBCs, the transporter is monotonically inhibited as O 2 tension is reduced with peak activity observed in fully oxygenated RBCs, and a P 50 for O 2 close to that of O 2 binding to Hb. The mechanism by which O 2 has its effects has recently been elucidated by the work of Low and colleagues (Chu et al. 2016; Zheng et al. 2018) , who propose that enhanced binding of deoxygenated Hb to band 3 displaces glycolytic and other enzymes, notably WNK1, leading to inhibition of the transporter. In sickle cells, as O 2 levels are reduced, the activity of KCC goes through a nadir at about half saturation of Hb for O 2 (Gibson et al. 1998) . At lower O 2 tensions, activity increases again such that in fully deoxygenated RBCs activity is similar if not slightly higher than that under fully oxygenated conditions. This O 2 -dependent behavior was confirmed in the present work. Nevertheless, GBT1118 inhibited KCC activity at the three O 2 tensions investigated. In addition, GBT1118 remained active in NEM-treated RBCs, indicative of a direct inhibitory effect on the transporter, rather than through the regulatory phosphorylation.
Consistent with marked inhibitory action on the dehydrating ion pathways, GBT1118 was found to protect RBC hydration under fully oxygenated and fully deoxygenated conditions. Similar effects on cation transport and RBC hydration have been observed previously with the heterocyclic aldehyde 5HMF (Hannemann et al. 2014) .
In the final series of experiments, GBT1118 was tested on an in vitro hemolysis assay (Browning et al. 2007; Milligan et al. 2013) . RBCs were suspended in deoxygenated isosmotic sucrose solutions. Under these conditions, progressive hemolysis is observed in RBCs from SCA patients but not those from normal individuals (HbAA). GBT1118 showed marked protection against lysis, indicative of a reduction in RBC fragility.
The present work suggests that GBT1118 may have considerable protective effects on sickle RBCs. First, through increasing O 2 affinity of HbS, reducing polymerization and sickling; second, through reduction in [HbS] which will also increase the lag time to HbS polymerization even if O 2 levels fall sufficiently to precipitate eventual sickling; and, third, through stabilizing the RBC membrane and protecting against hemolysis.
